Zug, Switzerland, 5 March -- PSI, a full-service global CRO known for on-time patient enrollment and project delivery, announces 2011 results reporting record growth in new client wins and 25% year-over-year revenue increase. PSI has helped pharmaceutical and biotechnology companies around the world adapt to evolving demands and increased complexity of clinical trials of new pharmaceuticals in a variety of therapeutic areas, insuring predictability of delivery timelines and reducing the R&D spend.
Feasibility services, Project Management, Medical Affairs, Data Management and Statistics were once again the top performing divisions of PSI. With 250 MDs on board, PSI continues to be one of the best medically qualified CROs in the industry. Its vast client base was strengthened by many new pharmaceutical client wins in 2011.
PSI, well known for its unparalleled operational strengths in Central and Eastern Europe, continued growth worldwide, now providing a wide range of clinical trial services in more than 50 countries. PSI’s focus, however, has not changed. It is all about timely delivery of patient enrollment insured by thorough feasibility driven by the company medics. “New clinical trials need new global CROs”, said Martin Schmidt, PSI’s Managing Director. – “The ones that are on-time”.
PSI (www.psi-cro.com) is a global, full-service CRO with 1,200 employees worldwide. PSI are experts in a variety of therapeutic areas, including oncology, hematology, neurology, infectious diseases, CNS, cardiovascular, metabolic diseases, etc.